Hyperoside was ultimately found to exert its anti-leukemic effects through the induction of NRF2/SLC7A11/GPX4 pathway-mediated ferroptosis within CML cells (Fig. 7). This evidence concerns the gene SLC7A11 and chronic myelogenous leukemia, BCR-ABL1 positive.